Zevra Therapeutics surges after Q4 earnings crush estimates
Rare disease biotech swings to full-year profitability as MIPLYFFA treatment reaches 68% market access
Zevra Therapeutics shares jumped in Tuesday trading after the rare disease biotechnology company reported fourth-quarter earnings that crushed analyst expectations, marking a dramatic turnaround to profitability for the full year 2025.
The Celebration, Florida-based company reported fourth-quarter earnings per share of $0.19, shattering Wall Street estimates of a $0.02 loss. Revenue for the quarter reached $34.1 million, beating projections of $26.6 million by 28 percent and representing 31 percent sequential growth.
The quarterly results capped a transformative year for Zevra, which swung to full-year 2025 net income of $83.2 million compared to a net loss of $105.5 million in fiscal 2024. The company achieved total net revenue of $106.5 million for the year, driven primarily by growth in its MIPLYFFA treatment.
MIPLYFFA, Zevra's proprietary treatment for rare diseases, generated $87.4 million in annual revenue and achieved 68 percent market access coverage, according to the company's financial release. Chief Executive Officer Neil McFarlane highlighted the momentum, stating that the "strong, accelerating performance reinforces our confidence in its long-term potential."
The company maintained a robust financial position with $238.9 million in cash, providing substantial runway for ongoing operations and development programs.
Zevra's transformation from loss-making to profitable has caught the attention of analysts. The stock currently carries a consensus analyst price target of $22.54, representing significant upside from current levels around $9.12. Of the eight analysts covering the company, all rate it as a buy or strong buy, with no hold or sell ratings, according to market data.
The company's market capitalization stands at approximately $505.6 million, with institutional investors holding 68.5 percent of outstanding shares. The stock has traded in a 52-week range between $6.19 and $13.16, reflecting heightened volatility typical of clinical-stage biotechnology companies transitioning to commercial revenue.
Zevra's proprietary platform focuses on developing prodrugs—modified versions of existing pharmaceutical compounds designed to improve therapeutic outcomes for serious medical conditions. The company's strategy centers on rare diseases where commercial opportunities may be underserved by larger pharmaceutical companies.
The profitability milestone represents a critical inflection point for Zevra, which previously burned through substantial cash developing its pipeline. The successful commercialization of MIPLYFFA demonstrates the company's ability to execute on its strategy of acquiring and optimizing treatments for niche patient populations.
Investors will be watching closely for updates on MIPLYFFA's continued market access expansion and any developments in Zevra's pipeline of additional rare disease treatments. The company's cash position provides flexibility to pursue both internal development and potential strategic acquisitions that could further diversify its revenue streams.
The fourth-quarter performance positions Zevra to build on its commercial momentum in 2026, with management signaling confidence in the long-term potential of its rare disease franchise. The company's ability to maintain its growth trajectory while expanding market access will be key factors driving investor sentiment going forward.